AzTrials
AzTrials

Kidney CalculiNCT04169165

Patient Compliance for Metabolic Evaluation and Medical Management in Calcium Stone Patients

An observational study of Kidney Calculi and Nephrolithiasis, run by EULIS Colloborative Research Working Group.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Calcium oxalate stone, the most common type worldwide, has a recurrence rate of around 50% in ten years. Therefore, identifying the underlying pathophysiological aspects via metabolic evaluation and suggestions for medical \& dietary prophylaxis in calcium stone patients is of upmost importance. Read more about this study

Who is it for?
Ages 18 to 80 years
How many people
500 participants
Where
No sites listed yet
Study dates
Jan 2020to Feb 2021
How long will I take part?
6 Months
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 80 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: All adult patients diagnosed with a calcium oxalate kidney stones and suggested for metabolic evaluation and dietary and/or medical management will be enrolled in the study.

Who may be able to join

  • Diagnosis of calcium oxalate kidney stones
  • Suggested metabolic evaluation for kidney stone
  • Suggested dietary and/or medical treatment for kidney stone
  • Accepted participation in the study

Who cannot join

  • Age less than 18
  • Mental disorders

Trial locations and contacts

No sites are listed yet.

Mehmet I Gökce, MD contact

+905333669130

migokce@yahoo.com

About this study

Official title: How to Improve Patient Compliance for Metabolic Evaluation and Medical & Dietary Prophylaxis in Calcium Stone Patients?

Calcium oxalate stone, the most common type worldwide, has a recurrence rate of around 50% in ten years. Therefore, identifying the underlying pathophysiological aspects via metabolic evaluation and suggestions for medical \& dietary prophylaxis in calcium stone patients is of upmost importance.

However, one of the greatest problem with metabolic evaluation and subsequent therapeutic advices is the patient compliance. Therefore, it is important to identify factors related to patient compliance for metabolic evaluation and medical \& dietary prophylaxis in calcium stone patients

Read the detailed description

Nephrolithiasis is an important health problem that can deteriorate the renal functions in long term and affects the patients' quality of life. One of the major problems about renal stones is the high rate of recurrence. Calcium oxalate stone, the most common type worldwide, has a recurrence rate of around 50% in ten years. Therefore, identifying the underlying pathophysiological aspects via metabolic evaluation and suggestions for medical \& dietary prophylaxis in calcium stone patients is of upmost importance.

However, one of the greatest problem with metabolic evaluation and subsequent therapeutic advices is the patient compliance. In the previous studies, even in case of a dedicated stone clinic, the drop out rate for preventive measures were over 37% per year. The patients' non-compliance may be related to a number of factors associated with the stone clinic, demographic characteristics of the patients, past medical history of the patients, and even the recommended tests and the therapeutic advices.

Therefore, it is important to identify factors related to patient compliance for metabolic evaluation and medical \& dietary prophylaxis in calcium stone patients

Methods:

Parameters to be recorded

Age Gender Level of education

  • of stone episodes
  • of surgical intervention Type of surgical intervention History of SWL Concomitant diseases Other medications Type of metabolic evaluation (24 hour urine, spot morning urine, serum etc.) Drug for medical prophylaxis Dosage of medication (bid/tid, etc.) Side effects Dietary recommendations Compliance to metabolic evaluation Compliance to medical treatment

Statistics:

Patients will be grouped based on:

compliance to metabolic evaluation compliance to medical treatment

The parameters listed above will be compared between the groups with univariate analysis (logistic regression).

Keywords
kidney stone, calcium oxalate stone, patient compliance, nephrolithiasis
Medical subject headings
Kidney Calculi, Nephrolithiasis, Patient Compliance, Nephrolithiasis, Calcium Oxalate

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT04169165
Study groupRoleWhat they receive
compliant patientsPatients with compliance to suggestions on metabolic evaluation and dietary/medical advices
non-compliant patientPatients without compliance to suggestions on metabolic evaluation and dietary/medical advices

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. patient compliance rate of metabolic evaluation

    the rate of the patients undergo metabolic evaluation tests will be determined

    Measured: 30 days

  2. patient compliance rate of dietary suggestions

    the rate of the patients that follow the dietary suggestions will be determined

    Measured: 6 months

  3. patient compliance rate of drug treatments

    the rate of the patients that have the prescribed drugs will be determined

    Measured: 6 months

Secondary outcomes (3)
  1. factors associated with non-compliance to metabolic evaluation

    the factors that are related to poor patient compliance to metabolic evaluation will be determined in multivariate analysis

    Measured: 3 months

  2. factors associated with non-compliance to dietary suggestions

    the factors that are related to poor patient compliance to dietary suggestions will be determined in multivariate analysis

    Measured: 3 months

  3. factors associated with non-compliance to medications

    the factors that are related to poor patient compliance to medications will be determined in multivariate analysis

    Measured: 3 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted19 Nov 2019
  2. Study startJan 2020 (estimated)
  3. Primary completionDec 2020 (estimated)
  4. Study completionFeb 2021 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
500 participants (estimated)
Target duration
6 Months
IDs, dates and publications
ClinicalTrials.gov ID
NCT04169165
Sponsor's protocol ID
eCORE-S-19-001
Status last verified
Nov 2019
First submitted
16 Nov 2019
Last updated
19 Nov 2019
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: All centers will enter their data for every single patient to an online database. The participating centers will be provided a username and a password to enter to the system. All centers will see the data of their own patients and only the number of patients enrolled from other centers.

Publications

  • Hess B. Renal stone clinic survey: calcium stone formers' self-declared understanding of and adherence to physician's recommendations. Urolithiasis. 2017 Aug;45(4):363-370. doi: 10.1007/s00240-016-0916-3. Epub 2016 Aug 29.

    PubMed 27573100
  • Prezioso D, Strazzullo P, Lotti T, Bianchi G, Borghi L, Caione P, Carini M, Caudarella R, Ferraro M, Gambaro G, Gelosa M, Guttilla A, Illiano E, Martino M, Meschi T, Messa P, Miano R, Napodano G, Nouvenne A, Rendina D, Rocco F, Rosa M, Sanseverino R, Salerno A, Spatafora S, Tasca A, Ticinesi A, Travaglini F, Trinchieri A, Vespasiani G, Zattoni F; CLU Working Group. Dietary treatment of urinary risk factors for renal stone formation. A review of CLU Working Group. Arch Ital Urol Androl. 2015 Jul 7;87(2):105-20. doi: 10.4081/aiua.2015.2.105.

    PubMed 26150027
  • Trinchieri A. Diet and renal stone formation. Minerva Med. 2013 Feb;104(1):41-54.

    PubMed 23392537
  • Skolarikos A, Straub M, Knoll T, Sarica K, Seitz C, Petrik A, Turk C. Metabolic evaluation and recurrence prevention for urinary stone patients: EAU guidelines. Eur Urol. 2015 Apr;67(4):750-63. doi: 10.1016/j.eururo.2014.10.029. Epub 2014 Nov 20.

    PubMed 25454613
  • Bensalah K, Tuncel A, Raman JD, Bagrodia A, Pearle M, Lotan Y. How physician and patient perceptions differ regarding medical management of stone disease. J Urol. 2009 Sep;182(3):998-1004. doi: 10.1016/j.juro.2009.05.025. Epub 2009 Jul 18.

    PubMed 19616801
  • Parks JH, Asplin JR, Coe FL. Patient adherence to long-term medical treatment of kidney stones. J Urol. 2001 Dec;166(6):2057-60.

    PubMed 11696706
  • Dauw CA, Yi Y, Bierlein MJ, Yan P, Alruwaily AF, Ghani KR, Wolf JS Jr, Hollenbeck BK, Hollingsworth JM. Medication Nonadherence and Effectiveness of Preventive Pharmacological Therapy for Kidney Stones. J Urol. 2016 Mar;195(3):648-52. doi: 10.1016/j.juro.2015.10.082. Epub 2015 Oct 17.

    PubMed 26485048
  • Pietrow P, Auge BK, Weizer AZ, Delvecchio FC, Silverstein AD, Mathias B, Albala DM, Preminger GM. Durability of the medical management of cystinuria. J Urol. 2003 Jan;169(1):68-70. doi: 10.1016/S0022-5347(05)64037-2.

    PubMed 12478105

Questions about this trial

What is this clinical trial studying?

An observational study of Kidney Calculi and Nephrolithiasis, run by EULIS Colloborative Research Working Group.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 19 Nov 2019. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Mehmet I Gökce, MD (+905333669130, migokce@yahoo.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

patient compliance rate of metabolic evaluation (time frame: 30 days). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04169165, which also lists 8 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Nov 2019.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in